These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27766053)

  • 41. Platelet C-Type Lectin-Like Receptor 2 Reduces Cholestatic Liver Injury in Mice.
    Maruyama S; Kono H; Furuya S; Shimizu H; Saito R; Shoda K; Akaike H; Hosomura N; Kawaguchi Y; Amemiya H; Kawaida H; Sudo M; Inoue S; Shirai T; Suzuki-Inoue K; Ichikawa D
    Am J Pathol; 2020 Sep; 190(9):1833-1842. PubMed ID: 32473917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelet CLEC-2 protects against lung injury via effects of its ligand podoplanin on inflammatory alveolar macrophages in the mouse.
    Lax S; Rayes J; Wichaiyo S; Haining EJ; Lowe K; Grygielska B; Laloo R; Flodby P; Borok Z; Crandall ED; Thickett DR; Watson SP
    Am J Physiol Lung Cell Mol Physiol; 2017 Dec; 313(6):L1016-L1029. PubMed ID: 28839100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization.
    Lee JY; Park C; Cho YP; Lee E; Kim H; Kim P; Yun SH; Yoon YS
    Circulation; 2010 Oct; 122(14):1413-25. PubMed ID: 20855662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TULA-2 Deficiency Enhances Platelet Functional Responses to CLEC-2 Agonists.
    Kostyak JC; Mauri BR; Dangelmaier C; Patel A; Zhou Y; Eble JA; Tsygankov AY; McKenzie SE; Kunapuli SP
    TH Open; 2018 Oct; 2(4):e411-e419. PubMed ID: 31249969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.
    Tsukiji N; Osada M; Sasaki T; Shirai T; Satoh K; Inoue O; Umetani N; Mochizuki C; Saito T; Kojima S; Shinmori H; Ozaki Y; Suzuki-Inoue K
    Blood Adv; 2018 Sep; 2(17):2214-2225. PubMed ID: 30190281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes.
    Tanaka K; Tanaka M; Watanabe N; Ito M; Pastan I; Koizumi M; Matsusaka T
    Sci Rep; 2022 Dec; 12(1):22356. PubMed ID: 36572741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombomodulation via CLEC-2 targeting.
    O'Callaghan CA
    Curr Opin Pharmacol; 2009 Apr; 9(2):90-5. PubMed ID: 19091630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of CLEC-2 and Its Ligands in Thromboinflammation.
    Meng D; Luo M; Liu B
    Front Immunol; 2021; 12():688643. PubMed ID: 34177942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphovenous hemostasis and the role of platelets in regulating lymphatic flow and lymphatic vessel maturation.
    Welsh JD; Kahn ML; Sweet DT
    Blood; 2016 Sep; 128(9):1169-73. PubMed ID: 27385789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Podoplanin expression in advanced atherosclerotic lesions of human aortas.
    Hatakeyama K; Kaneko MK; Kato Y; Ishikawa T; Nishihira K; Tsujimoto Y; Shibata Y; Ozaki Y; Asada Y
    Thromb Res; 2012 Apr; 129(4):e70-6. PubMed ID: 22283975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The podoplanin-CLEC-2 axis inhibits inflammation in sepsis.
    Rayes J; Lax S; Wichaiyo S; Watson SK; Di Y; Lombard S; Grygielska B; Smith SW; Skordilis K; Watson SP
    Nat Commun; 2017 Dec; 8(1):2239. PubMed ID: 29269852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development.
    Lowe KL; Finney BA; Deppermann C; Hägerling R; Gazit SL; Frampton J; Buckley C; Camerer E; Nieswandt B; Kiefer F; Watson SP
    Blood; 2015 Jun; 125(24):3769-77. PubMed ID: 25908104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abnormalities in C-type lectin-like receptor 2 in a patient with Gorham-Stout disease: the first case report.
    Oishi S; Tsukiji N; Segawa T; Takano K; Hasuda N; Suzuki-Inoue K
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102273. PubMed ID: 38187828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CLEC-2 is required for development and maintenance of lymph nodes.
    Bénézech C; Nayar S; Finney BA; Withers DR; Lowe K; Desanti GE; Marriott CL; Watson SP; Caamaño JH; Buckley CD; Barone F
    Blood; 2014 May; 123(20):3200-7. PubMed ID: 24532804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CLEC-2 and podoplanin, partners again.
    Fu J; Xia L
    Blood; 2016 Mar; 127(13):1629-30. PubMed ID: 27034419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2.
    Chaipan C; Steffen I; Tsegaye TS; Bertram S; Glowacka I; Kato Y; Schmökel J; Münch J; Simmons G; Gerardy-Schahn R; Pöhlmann S
    Retrovirology; 2010 May; 7():47. PubMed ID: 20482880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelets Regulate the Migration of Keratinocytes via Podoplanin/CLEC-2 Signaling during Cutaneous Wound Healing in Mice.
    Asai J; Hirakawa S; Sakabe J; Kishida T; Wada M; Nakamura N; Takenaka H; Mazda O; Urano T; Suzuki-Inoue K; Tokura Y; Katoh N
    Am J Pathol; 2016 Jan; 186(1):101-8. PubMed ID: 26597882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2).
    Bruserud Ø
    Toxins (Basel); 2013 Apr; 5(4):665-74. PubMed ID: 23594438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A change of rhodocytin's suprastructure turns the agonist into an antagonist of tumor cell induced platelet aggregation.
    Obermann WMJ; König S; Feickert MK; Sanz-Soler R; Eble JA
    FASEB J; 2024 Jan; 38(2):e23402. PubMed ID: 38193585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.